462 related articles for article (PubMed ID: 23395844)
21. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
22. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.
Mercatali L; Spadazzi C; Miserocchi G; Liverani C; De Vita A; Bongiovanni A; Recine F; Amadori D; Ibrahim T
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27809291
[TBL] [Abstract][Full Text] [Related]
25. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
26. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
[TBL] [Abstract][Full Text] [Related]
27. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
29. Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Tardoski S; Ngo J; Gineyts E; Roux JP; Clézardin P; Melodelima D
Sci Rep; 2015 Nov; 5():16354. PubMed ID: 26578234
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
31. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
Bühler H; Hoberg C; Fakhrian K; Adamietz IA
In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
[TBL] [Abstract][Full Text] [Related]
34. Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts in vitro.
Kadow-Romacker A; Greiner S; Schmidmaier G; Wildemann B
J Biomater Appl; 2013 Jan; 27(5):577-85. PubMed ID: 21862509
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
36. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
37. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
[TBL] [Abstract][Full Text] [Related]
38. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
Ohshiba T; Miyaura C; Inada M; Ito A
Br J Cancer; 2003 Apr; 88(8):1318-26. PubMed ID: 12698202
[TBL] [Abstract][Full Text] [Related]
39. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor.
Morgan H; Tumber A; Hill PA
Int J Cancer; 2004 May; 109(5):653-60. PubMed ID: 14999770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
